The AAT program may be partnered by LFB, in which case costs and potential profits will be split 50/50 between LFB and GTC. A decision on this need not be made until the program is closer to entering clinical development.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”